MFDS Approves Rare Hemophilia A Treatment "Altuvio Injection"
The Ministry of Food and Drug Safety announced on December 23 that it has approved the import of the rare drug "Altuvio Injection" (active ingredient: efanesoctocog alfa).
This medication is a recombinant coagulation factor VIII agent for the prevention and management of bleeding in adults and children with hemophilia A. Compared to previously approved drugs, it has an extended half-life, allowing for once-weekly dosing as a long-acting therapy.
Congenital hemophilia A is a rare blood disorder characterized by a deficiency of coagulation factor VIII, which can cause life-threatening bleeding in response to trauma, as well as recurrent bleeding into soft tissues and joints.
The Ministry designated this drug as a target for the Global Innovative Product Fast-Track (GIFT) review system and expedited its review and approval.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Ministry official stated, "We expect that treatment accessibility for adult and pediatric patients with congenital hemophilia A will be improved," adding, "We will continue to do our best to ensure that safe and effective therapies for life-threatening, rare, or serious diseases can be supplied quickly."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.